Pediatrics & Therapeutics
Open Access

Acute myeloid leukemia-M6 - Case report in a 2-year-old boy

World Congress on Clinical Pediatrics and Pediatric Oncology & Care

November 12-13, 2018 | Lisbon, Portugal

Carolina Maria Costa Pavao,Silvia Silva, Catia Sousa, Filipa Leite, CatarinaSousa, Marta Almeida, Ana Maia Ferreira, VitorCosta, Tereza Oliva and Armando Pinto

Hospital do Divino Espirito Santo, Portugal

Instituto Portugues de Oncologia do Porto, Portugal

Scientific Tracks Abstracts: Pediatr Ther

Abstract :

Acute myeloid leukemia (AML) M6 or acute erythroid leukemia is an extremely rare type of leukemia and in children is even rarer (about 0.5â??4.6% of all cancer-affected individuals are children). We report a case of a 2-year-old boy who started complaints of pain in the lower left leg, more specifically at the tibio-tarsal joint (site of fracture one 1 year before), with progressive aggravation, imbalance in gait and associated with B symptoms, which motivated the mother to seek medical assistance. Analytical study documented anemia of 10.7 g/dL, leukocytes of 10570 /uL, thrombocytopenia of 69000 / uL and DHL of 585 U/L. Objective examination was normal apart from imbalance in gait. Parvovirus serology was negative. In subsequent analyzes 3% blasts of the erythroid line were detected in the peripheral blood. Medullary aspirate was difficult to perform, and the first samples were very hypocelular. Immunophenotyping of bone marrow showed in the beginning 4% of erythroblasts, then 1%, 3% and 0.09% in subsequent samples. Bone marrow biopsy showed involvement by acute leukemia with erythroblastic differentiation. Cytogenetics of bone marrow demonstrate a complex karyotype. There was no infiltration of central nervous system. In spite of a low percentage of blasts in the bone marrow, and given that there was a diagnosis by pathological anatomy and a notion of clinical worsening (the child was very asthenic and with generalization of bone pain), it was decided to start treatment according to NOPHO AML 2012 protocol. Treatment was finished in March 2017 with complete response.

Biography :

Carolina Maria Costa Pavão has completed her MD with master degree in 2014 from the Faculty of Medicine of the University of Coimbra. Started her residency in clinical hematology in the hematology service of the Hospital do Divino Espírito Santo, Ponta Delgada, Portugal, in January of 2016, being currently attending the third year of her specific five year formation. As part of this programme she completed an intership in oncology pediatrics at Porto Oncology Institute in 2018.

E-mail: carolina.mcpavao@gmail.com